Form 4: Nuvalent's Chief Legal Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 12, 2024, Deborah Ann Miller, the Chief Legal Officer of Nuvalent, Inc., executed a transaction involving the company's stock.
• Miller exercised stock options to acquire 6,000 shares of Class A Common Stock at a price of $27.85 per share.
• Simultaneously, Miller sold 6,000 shares of Class A Common Stock at a weighted average price of $80.16, with prices ranging from $80.00 to $80.54.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Miller directly owns 33,300 shares of Class A Common Stock and holds options for 96,154 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and the sale price indicates a positive valuation of the company's stock. However, insider sales can sometimes create uncertainty.

Positives

• The transactions were executed under a pre-existing Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
• The sale price of $80.16 is significantly higher than the option exercise price of $27.85, indicating a substantial profit for the reporting person.

Risks

• While the Rule 10b5-1 plan mitigates some concerns, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

Insider transactions are common and closely monitored, especially in publicly traded companies. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among corporate executives to manage their stock sales and avoid accusations of insider trading.
• The spread between the exercise price ($27.85) and the sale price ($80.16) is substantial, reflecting the company's stock performance since the options were granted.
• Comparing this transaction to similar filings by executives at comparable biotech companies would provide further context on the scale and frequency of such activities.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on how the market interprets the insider sale.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates